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Background: Tumor Associated Antigens are characterized by spontaneous immune response in cancer patients as
a consequence of overexpression and epitope-presentation on MHC class I/II machinery. Matrix Metalloprotease 11
(MMP11) expression has been associated with poor prognosis for several cancer types, including breast and prostate
cancer.
Methods: MMP11 expression was determined by immunoistochemistry in breast and prostate cancer samples.
Circulating MMP11 protein as well as the spontaneous immune responses against MMP11 were analyzed in a set of
breast and prostate cancer patients.
Results: In plasma samples MMP11 protein was present in 5/13 breast cancer patients and in 1/12 prostate
cancer patients. An antibody response was observed in 7/13 breast cancer patients and in 3/12 prostate cancer
patients.
Conclusions: These findings further suggest MMP11 as a promising biomarker for these tumor types and a
suitable target for cancer immunotherapy strategies.
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Cancer is essentially considered a complex cell disease.
However, in recent decades increasing research of the
tumoral microenvironment has revealed the crucial role
of stromal cells and host’s immune system in determin-
ing the neoplastic phenotype [1-3]. Therefore, cancer
could be explained, at least in part, as a complex inter-
action with different cell types and an abnormal immune
system tolerance to uncontrolled cancer cells.
The therapeutic potential of targeting tumor stroma
has been shown in several preclinical and clinical stud-
ies. T cells and antibodies represent an important alter-
native approach to the effective control of tumor growth,
particularly in the absence of direct targeting of cancer
cells [4]. Cellular targets of active immune interventions
include cancer-associated fibroblasts, infiltrating macro-
phages/histiocytes, and tumor endothelial cells. Antigens* Correspondence: luigi.aurisicchio@gmail.com
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reproduction in any medium, provided the oras carbonic anhydrase IX or fibroblast activation protein
(FAP) α suggest that vaccination against stromal antigens
is a feasible approach for anticancer therapy [5]. Matrix
metalloproteases (MMP) are overexpressed and contrib-
ute to neoplastic phenotype and metastatic activity [6,7].
Immunologic targeting of MMPs has been suggested in
several studies. The antitumoral effects of a vaccine
against MMP2 have been reported [8]. MMP7 was identi-
fied as a novel broadly expressed tumor-associated antigen
and a T-cell epitope derived from this protein was pro-
posed as candidate for vaccine development [9]. These ob-
servations show that MMPs are valid candidates for
antigen-specific immunotherapy.
Recently, our group has shown that MMP11 may rep-
resent an ideal self-antigen for immunotherapy. It is dif-
ferentially expressed in tumor versus normal tissue [10],
although it is unclear if it is expressed in cancer cells or
in the supporting stroma. A genetic vaccine against
MMP11 based on DNA electro-gene-transfer technology
was able to break immune tolerance and exert antitumor
effects in a chemically-induced colon adenocarcinomaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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mediated and antibody response was elicited by this
vaccine. Levels of MMP11 expression may be used to
identify patients at greatest risk for cancer recurrence,
in breast carcinoma, pancreatic tumors [11] and colon
cancer [12]. Furthermore, the prognostic significance
of MMP11 expression was further confirmed for breast
cancer [13] and shown for prostate cancer [14]. MMP11 is
processed intracellularly and secreted as an active form
[15]. MMP11 thus differs from other MMPs that are
expressed as proenzymes and processed to active forms
through proteolytic cleavage activated extracellularly, indi-
cating that MMP11 may have a unique role in tumor de-
velopment and progression [16].
Tumor Associated Antigens (TAAs) are characterized
by spontaneous immune response in cancer patients as a
consequence of overexpression, shedding and epitope-
presentation on MHC class I/II machinery. For instance,
spontaneous antibodies against HER2, Carcinoembryo-
nic Antigen (CEA), p53 and cyclin B1 are commonly de-
tected in patients affected by breast cancer [17,18] and
multiple autoantibodies are dectected in Hepatocarci-
noma patients [19]. However, these antibodies do not
reach a titer sufficient to exert antitumor effects.
To assess whether the overexpression of MMP11 in
cancer patients may spontaneously induce a specific im-
mune response, in this study we have confirmed the ex-
pression of the protein in breast and prostate tumor
microenvironment and then we have measured circulat-
ing MMP11 protein and anti-MMP11 antibodies in a set
of breast and prostate cancer patients. Our findings val-
idate MMP11 as a potential biomarker for these tumor
types and a suitable target for cancer immunotherapy
strategies.
Methods
Tissue specimens and immunoistochemical staining
Archival pathological tissue specimens were obtained at
Sant’Andrea Hospital in Rome from 11 patients with
HER2-positive invasive ductal carcinoma of the breast
and from 5 invasive prostate adenocarcinomas. Paraffin
tissue sections were immunostained with a rabbit mono-
clonal antibody anti-MMP11 (clone EP1259Y, dilution
1:200, Abcam, Cambridge, UK) using an automated immu-
nostainer (DAKO, Denmark).
Human plasma samples
They were obtained from the Pathology Unit, Saint
Savas Hospital and were kindly provided by Dr CN
Baxevanis. All tissue samples were clinicopathologically
assessed. Samples of healthy donors were used as
negative controls and obtained at Sant’Andrea Hospital,
University of Rome. All patients voluntarily provided
their blood for research purposes.Detection of MMP11 protein
MMP11 protein in plasma samples was detected by
ELISA. MMP11 ELISA assay was first optimized using
extracts from HeLa cells (ATCC) transfected in 6 cm
dishes with 5 μg pV1J-hMMP11 plasmid [10] using
Lipofectamine 2000 (Gibco). 48 hr later, cells were lysed
in RIPA buffer containing Protease inhibitors (cOmplete
Protease Inhibitor Cocktail, Roche). Briefly cell pellet
(about 1×106 cells) was resuspended in 200 μL of cold
RIPA buffer and incubated on ice for 15 min. Lysate was
then cleared by centrifugation (14000 RPM, 10 min, 4°C)
and total protein concentration was determined by
Bradford assay.
Capture ELISA was done using a polyclonal rabbit
anti-MMP11 antibody (Abcam, ab53143) coated onto 96
well plates (Nunc Maxisorp) at 1 μg/ml over night at 4°C.
Wells were blocked with Tris-buffered solution, 0.05%
Tween 20 (TBST) and 3% bovine serum albumin (block-
ing buffer), 100 μL per well for 2 hours at room
temperature. The wells were incubated with patient
plasma diluted 1:10 and 1:100 in TBST + 1% bovine serum
albumin for 2 hours at room temperature. After washing
three times in TBST, a mouse monoclonal anti-MMP11
antibody (Novus Biologicals, SL3-01) was added to the
wells at a 1:100 dilution in blocking buffer and incubated
for 2 hrs at room temperature. An HRP conjugated anti-
mouse IgG (Abcam) diluted 1/1000 was used as detection
agent following 3 washings in TBST. TMB developing re-
agent (Pierce) was added and the reaction stopped with
1 N HCl and the absorbance read at 450 nm. MMP11
levels were quantitated by comparison to a standard curve
using a commercial MMP11 protein (Abcam, ab92861) at
several dilutions. The assay specificity was optimized as
described in Additional file 1: Figure S1. The sensitivity in
different biological fluids such as cell supernatants or hu-
man plasma was determined as described in Additional
file 2: Figure S2. SuperBlock blocking buffer (Pierce) and
LI-COR buffer (LI-COR Biosciences) were also evaluated.
The assay sensitivity was about 50 ng/ml.
Detection of anti-MMP11 autoantibodies
Recombinant human MMP11 protein (Abcam) was coated
at 100 ng/well onto 96 well plates (Nunc Maxisorp) in PBS
over night at 4°C. Wells were blocked with PBS, 3% bovine
serum albumin, 100 μL per well for 2 hours at room
temperature. Plasma samples were added at 1:20 to 1:540
dilution in PBS, 1% bovine serum albumin, 100 μL per
well and incubated over night at 4°C. The day after, an
AP-conjugated anti-human IgG (Sigma) diluted 1:2000
in PBS, 1% bovine serum albumin and incubated at
room temperature for 1 hr was used as detection agent.
The Alkaline Phosphatase Yellow (pNPP) liquid sub-
strate system (Sigma) was used and absorbance mea-
sured at 405 nm.
Figure 1 Representative images of immunostaining with anti-
MMP11 in breast (A, B) and in prostate (C) cancer (original
magnification x200). In A immunoreactivity for MMP11 was
observed in the cytoplasm of the invasive ductal carcinoma cells
and in the fibrous stroma. In B only peritumoral fibroblasts were
positive. In C prostate cancer cells showed a strong cytoplasmic
staining; intermingled normal glands were completely negative or
faintly positive.
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MMP11 protein expression in invasive breast and
prostate cancer
In order to evaluate MMP11 protein expression in inva-
sive breast and prostate cancer, 11 HER2-positive invasive
ductal carcinoma of the breast and 5 invasive prostate
adenocarcinomas were immunostained for MMP11
(Figure 1). Positive cytoplasmic staining was observed
in 3/11 breast carcinomas (Figure 1A). Of the remaining
cases 3 showed immunoreactivity only in the peritumoral
fibroblasts (Figure 1B), and 5 were completely negative.
No significant staining was observed in normal mammary
glands. Prostate cancers showed a strong cytoplasmic
staining in 3/5 cases (Figure 1C). Normal prostate glands
were completely negative or occasionally weakly positive.
Cancer patients characteristics
We collected 13 plasma samples from breast cancer pa-
tients and 12 from prostate cancer patients. In addition, we
used 7 samples from healthy donors as negative controls.
All breast cancer patients had HER-2-positive histologically
confirmed primary invasive breast adenocarcinoma with
no evidence of residual, locally recurrent, or metastatic dis-
ease after completion of surgery and chemotherapy (neo-
adjuvant or adjuvant), an ECOG performance status of 0
or 1, and were under Trastuzumab treatment.
Prostate cancer patients had documented non meta-
static castration-resistant prostate cancer determined by
increasing serum PSA despite castrate levels of testoster-
one (<50 ng/dL), with no radiographic evidence of meta-
static disease. Mean Gleason score 7 (range: 3–9).
Detection of circulating MMP11 protein
As previously shown, MMP11 expression in breast and
prostate cancer was confirmed by IHC in a high percent-
age of cases with similar characteristics (Figure 1).
Among the metalloproteases, MMP11 is the only en-
zyme secreted in an active form [15]. To date, an assay
to specifically detect and quantify MMP11 catalytic ac-
tivity in biological samples has not yet been established.
To see whether the protein could be detected in the blood,
we have set up an ELISA assay (see Methods) by means of
two commercial antibodies and adapted it to different bio-
logic fluids, such as cell extracts, supernatants and blood
plasma. To establish the assay with a protein endowed of
similar features and post-translational modifications found
in patients, the assay was optimized using cell extracts de-
rived from HeLa transfected with a human MMP11 ex-
pression vector [10]. Results are shown in Additional file 1:
Figure S1 and Additional file 2: Figure S2 and indicate that
plasma matrix does not affect the overall assay perform-
ance and sensitivity. Based on this observation, MMP11
was evaluated in 13 breast and 12 prostate cancer plasma
samples, respectively, compared to a healthy donor cohort.To define a standardized threshold of the ELISA assay, a
signal mean value plus 3 times the standard deviation was
calculated from 6 healthy donors, corresponding to
102.7 ng/ml (44.7 + 3*19.34 ng/ml). In this setting, circulat-
ing MMP11 was detected at different levels in 5 out of 13
breast cancer patients as well as in 3 out of 12 prostate
cancer patients. A lower expression level was measured in

















































































































































































Figure 2 MMP11 detection in plasma samples. A) standard curve of the ELISA assay. MMP11 recombinant protein was diluted in 1:10 dilution
of a normal control plasma. B) MMP11 was measured by ELISA in breast (BR) and prostate (PROST) cancer plasma samples as described in
Methods. Control (C) samples were obtained from healthy donors. The assay was run in duplicate and repeated twice, with a inter-variability of
7.6%. A threshold at 100 ng/ml was determined (see text) to identify positive and negative plasma samples.
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To assess whether MMP11 could spontaneously be rec-
ognized as an antigen by the immune system, MMP11
recombinant protein was immobilized and used to titrate
specific IgG antibodies in this cohorts of patients. An
antibody response was observed in 7/13 breast cancer
patients and in 2/12 prostate cancer patients (Figure 3).
No antibodies (0/6) were measured in healthy donors.
No association between MMP11 expression in the blood
and the presence of specific antibodies was found.
Conclusions
TAAs are important targets for immunization strategies
and for the development of therapeutic antibodies. Tar-
geting the tumor stroma as a cancer therapeutic ap-
proach has been established in several experimental and
clinical studies. Matrix metalloproteinases (MMPs) have
the desired properties as they are important components
of tumor stroma and are present in almost all human
cancers compared with normal tissue [6,7].In this study, we have confirmed the expression of
MMP11 in breast and prostate cancer (Figure 1) and for
the first time we have found its expression in blood-
stream and spontaneous autoantibodies in breast and
prostate cancer patients (Figures 2 and 3). The prognos-
tic significance of MMP11 expression for breast cancer
was recently confirmed by Cheng et al. [13]. Overex-
pression of MMP-11 correlates with patients having
poorly differentiated tumors, lymph node metastasis and
lacking progesterone receptor. Temporally increased
MMP-11 expression can be considered as an early event,
occurring prior to lymph node metastasis during breast
cancer progression. Similarly, MMP11 expression in pros-
tate cancer patients was significantly correlated with poor
differentiation in Gleason grading, pathologic tumor
stage4 (pT4), and positive-bone metastasis (p < 0.05), but
not age and prostatic-specific antigen (PSA) level. Patients
with high levels of MMP-11 expression demonstrated sig-
nificantly shorter survival (p < 0.001) when compared to
























































































































































Figure 3 Anti-MMP11 detection in plasma samples. MMP11 antibodies were measured by ELISA. Anti-MMP11 titers were calculated as the
reciprocal limiting dilution of plasma producing an absorbance at least 3-fold greater than the absorbance of control samples average at
the same dilution. The assay was run in duplicate and repeated twice. A threshold at 1:200 was arbitrarily set to identify seropositive patients.
BR, breast; PROST, prostate; C, controls.
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prognosis.
Our data show that MMP11 is indeed overexpressed
in a subset of breast and prostate cancer patients. In our
breast cancer specimens we were able to detect the ex-
pression either by the cancerous cells (Figure 1A) or by
the peritumoral fibroblasts (Figure 1B). We also found a
strong signal in 3/5 prostate cancer samples (Figure 1C).
The presence of autoantibodies is in line with this find-
ing. We are currently developing an assay to specifically
detect and quantify MMP11 catalytic activity on a syn-
thetic substrate peptide. Such assay will be instrumental
to assess whether spontaneous and induced antibodies
against MMP11 could have a biological role at inhibiting
its enzymatic activity. Moreover, it will be of interest to
find association among the circulating protein, the anti-
body titer and patients survival. We are currently follow-
ing up these patients, accumulating new data and
analyzing the IgG subtype to find potential associations.
A limitation of our study is the restricted data set and
the lack of match between MMP11 tumor expression
and plasma samples within the same patients popula-
tion. For this reason, our finding needs to be followed by
a confirmatory study with a larger cohort of patients.
Moreover, the observation that one healthy donor
(C015, Figure 2) showed a high level of circulating
MMP11 suggest that the protein may be involved in
other biologic processes and indicate that larger patients
cohorts and relative controls should be analyzed. In
addition, we are generating preclinical data in mouse
models that suggest that cell mediated immune response
may play an important role as effective arm of the im-
mune response as a consequence of an anti-MMP11
vaccination. A novel T-cell epitope derived from human
MMP11 (hMMP237) was identified in our lab by vaccin-
ation of HLA-A2.1 (HHD) transgenic mice and was shown
to be immunogenic by in vitro priming with humanPBMCs. Moreover, activated CTLs secrete granzyme B, a
key mediator of target cell death via the granule-mediated
pathway [10]. Thus, the immune response against hMMP237
represents a potential biomarker for induced and spontan-
eous immune response. We are currently analyzing by tetra-
mer staining and in vitro priming the T cell responses in
PBMCs from patients affected by different tumor types,
including breast and prostate cancer. It will be of interest to
correlate IHC, circulating protein, antibodies and T cell
responses with clinical behavior and survival outcome.
In conclusion, our study, albeit preliminary, further
suggest that MMP11 may act as a bona fide TAA and be
a suitable target for cancer immunotherapy.
Additional files
Additional file 1: Figure S1. Set up and Optimization of the ELISA
assay for detection of MMP11 protein. HeLa cells (MMP11 negative) were
plated onto 6 cm dishes and transfected with an expression vector for
MMP11 [10]. Two days later, cell lysates were prepared and incubated at
the indicated amount O/N in a 96 well plate previously coated with a
polyclonal rabbit anti-MMP11 antibody. After washing, plates were
incubated with a monoclonal mouse anti-MMP11 antibody and the
detection was executed with an anti-mouse IgG-HRP. Blocking and
incubation were performed in A) TBST + 1% BSA; B) TBST + 5% milk;
C) SuperBlock buffer; D) LICOR Blocking Buffer (BB), 0.1% Tween 20.
E) a direct comparison of the influence of the buffer on specific (HeLa
transfected) vs non-specific (HeLa mock treated) signal. The best
conditions were obtained with TBST + 1% BSA. HeLa NT indicates
mock transfected cells; HeLa-hMMP11 indicates cells transfected with the
expression vector.
Additional file 2: Figure S2. Sensitivity of the assay in different
biologic fluids. The assay was run with the conditions defined in
Additional file 1: Figure S1. MMP11 recombinant protein was diluted in
TBST + 1% BSA, cell culture medium (DMEM, 10% FCS) or TBST + human
plasma diluted 1:10. The signal at higher concentrations was reduced of
about 30% in the presence of plasma, but the sensitivity was similar in
the three conditions. The assay was run in triplicates and repeated twice
with similar results.
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